Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Crompton Greaves shares gain 4% after Macquarie retains outperform, sees 27% upside

2018-07-11 moneycontrol
Crompton Greaves Consumer Electrical share price rallied 4 percent intraday on Wednesday after global brokerage firm Macquarie maintained its outperform rating with a target price at Rs 292 per share, implying a 27 percent potential upside.
500093 CPGVY CGVA CROMPGREAV CGVD CPGZF

14
[Press] A Succinct Overview of Europe Oil Filled Distribution Transformer Market With a Regional Frame of Reference, Capacity Expansion Strategies to Characterise Industry Growth Over 2018-2024

2018-05-31 oilvoice
Over the recent years, Europe oil filled distribution transformer market share has been amplifying at a commendable pace owing to the expansion of cross-border distribution projects and massive investments directed toward modernizing the existing grid networks. The European Investment Bank has recently earmarked USD 5.1 billion for energy sector initiatives. The funds would be utilized to construct, expand, and revamp power generation projects across the nations such as France, Italy, Ireland, and Spain.
500093 GEC GE CPGVY GNE CGVA CROMPGREAV CGVD CPGZF

14
[Press] A succinct overview of Europe oil filled distribution transformer market with a regional frame of reference, capacity expansion strategies to characterize industry growth over 2018-2024

2018-05-27 oilvoice
Over the recent years, Europe oil filled distribution transformer market share has been amplifying at a commendable pace owing to the expansion of cross-border distribution projects and massive investments directed toward modernizing the existing grid networks. The European Investment Bank has recently earmarked USD 5.1 billion for energy sector initiatives. The funds would be utilized to construct, expand, and revamp power generation projects across the nations such as France, Italy, Ireland, and Spain.
500093 GEC GE CPGVY GNE CGVA CROMPGREAV CGVD CPGZF

14
[Press] A succinct overview of Europe oil filled distribution transformer market with a regional frame of reference, capacity expansion strategies to characterize industry growth over 2018-2024

2018-05-27 oilvoice
Over the recent years, Europe oil filled distribution transformer market share has been amplifying at a commendable pace owing to the expansion of cross-border distribution projects and massive investments directed toward modernizing the existing grid networks. The European Investment Bank has recently earmarked USD 5.1 billion for energy sector initiatives. The funds would be utilized to construct, expand, and revamp power generation projects across the nations such as France, Italy, Ireland, and Spain.
500093 GEC GE CPGVY GNE CGVA CROMPGREAV CGVD CPGZF

0
Broker's call: Crompton Greaves (Buy)

2018-04-25 thehindubusinessline
Crompton Greaves Consumer Electricals (CGCEL) likely to report a decent PAT growth by 19.3 per cent y-o-y to ₹100 crore in 4QFY18 while EBITDA margin seen improvement by 60 bps to 13.8 per cent led by improved margin in electrical consumer durable and lighting products business.
500093 CPGVY CGVA CROMPGREAV CGVD CPGZF

21
Essar Group sells Equinox Business Park to Brookfield

2018-04-24 livemint
Mumbai: Essar Group on Tuesday said it has completed the sale of Equinox Business Park, its commercial property in Mumbai’s Bandra-Kurla Complex, to Canada’s Brookfield Asset Management Inc. for Rs2,400 crore.
500093 BAMGF CPGVY CGVA TATACOMM CROMPGREAV 500483 BAMKF BAM CGVD CPGZF

0
Crompton Greaves expands product portfolio

2018-04-24 moneycontrol
Electrical appliances maker Crompton Greaves Consumer Electricals Ltd today unveiled a new range of fans and air-coolers as part of expansion of its product portfolio.
500093 CPGVY CGVA CROMPGREAV CGVD CPGZF

0
CGCEL CEO says aim to be among top 4 players in appliances market; open to acquisitions

2018-04-17 moneycontrol
Consumer durables company Crompton Greaves Consumer Electricals (CGCEL) has launched two new products in the fan and cooler space to meet the surging demand for products that can help beat the agonising heat.
500093 CPGVY CGVA CROMPGREAV CGVD CPGZF

20
19
News Live: Mood in Karnataka favours Congress, says Rahul Gandhi

2018-04-09 moneycontrol
Casualties reported in strike on Syria air base: state media A missile attack on a Syrian military airport left several dead and wounded, state media said today, after the US warned Damascus and its allies over an earlier suspected chemical attack on a rebel-held town.The strike on the Tayfur air base in the central province of Homs, came as international outrage mounts over an attack on Saturday in the rebel enclave of Eastern Ghouta.
BAJAJ-AUTO BHRYY CPGVY 500820 ADANIENT 532617 532977 512599 ASIANPAINT 532215 500093 505200 532483 AXISBANK 534816 HEROMOTOCO CGVA INFRATEL BEL EICHERMOT CGVD BHQRY ECQRY ABB ANNRY AXB JETAIRWAYS CROMPGREAV CPGZF CNRYY AXBKY 500182 AXBA 500002 ABBDY HRTQY 500049 CANBK

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...